Sphingopeptides: Dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1

FASEB Journal

Volumn 26, Issue 11, 2012, Pages 4628-4636

  Ashkenazi, Avraham ^a   Viard, Mathias ^b,c   Unger, Linor ^a   Blumenthal, Robert ^b   Shai, Yechiel ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b Nanobiology Program   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Sphingolipids; Viral envelope protein

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHOLESTEROL; ENFUVIRTIDE; FATTY ACID; SPHINGANINE N17; SPHINGOSINE; SPHINGOSINE C16 N17; TOCOPHEROL; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELL FUSION; CONTROLLED STUDY; DRUG BINDING; DRUG BINDING SITE; DRUG CONJUGATION; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; LEUKEMIA CELL LINE; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS STRAIN;

CELL FUSION; CELL LINE; CHOLESTEROL; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; PLASMA; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; SPHINGOMYELINS; SPHINGOSINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84868297922     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.12-215111     Document Type: Article

References (56)

1. White, J. M. (1990) Viral and cellular membrane fusion proteins. Annu. Rev. Physiol. 52, 675-697
2. Chernomordik, L. V., and Kozlov, M. M. (2008) Mechanics of membrane fusion. Nat. Struct. Mol. Biol. 15, 675-683
3. Nguyen, D. H., and Hildreth, J. E. (2000) Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J. Virol. 74, 3264-3272
4. Ono, A., and Freed, E. O. (2001) Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc. Natl. Acad. Sci. U. S. A. 98, 13925-13930
5. Viard, M., Parolini, I., Sargiacomo, M., Fecchi, K., Ramoni, C., Ablan, S., Ruscetti, F. W., Wang, J. M., and Blumenthal, R. (2002) Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J. Virol. 76, 11584-11595
6. Mahfoud, R., Garmy, N., Maresca, M., Yahi, N., Puigserver, A., and Fantini, J. (2002) Identification of a common sphingolipidbinding domain in Alzheimer, prion, and HIV-1 proteins. J. Biol. Chem. 277, 11292-11296
7. Takeda, M., Leser, G. P., Russell, C. J., and Lamb, R. A. (2003) Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion. Proc. Natl. Acad. Sci. U. S. A. 100, 14610-14617
8. Choi, K. S., Aizaki, H., and Lai, M. M. (2005) Murine coronavirus requires lipid rafts for virus entry and cell-cell fusion but not for virus release. J. Virol. 79, 9862-9871
9. Medigeshi, G. R., Hirsch, A. J., Streblow, D. N., Nikolich-Zugich, J., and Nelson, J. A. (2008) West Nile virus entry requires cholesterol-rich membrane microdomains and is independent of v 3 integrin. J. Virol. 82, 5212-5219
10. Brugger, B., Glass, B., Haberkant, P., Leibrecht, I., Wieland, F. T., and Krausslich, H. G. (2006) The HIV lipidome: a raft with an unusual composition. Proc. Natl. Acad. Sci. U. S. A. 103, 2641-2646
11. Simons, K., and Ikonen, E. (1997) Functional rafts in cell membranes. Nature 387, 569-572
12. Simons, K., and Gerl, M. J. (2010) Revitalizing membrane rafts: new tools and insights. Nat. Rev. Mol. Cell Biol. 11, 688-699
13. Berger, E. A., Murphy, P. M., and Farber, J. M. (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657-700
14. Eckert, D. M., and Kim, P. S. (2001) Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777-810
15. Gallo, S. A., Finnegan, C. M., Viard, M., Raviv, Y., Dimitrov, A., Rawat, S. S., Puri, A., Durell, S., and Blumenthal, R. (2003) The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 1614, 36-50
16. Chien, M. P., Jiang, S., and Chang, D. K. (2008) The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein-mediated cell fusion. FASEB J. 22, 1179-1192
17. Finzi, A., Xiang, S. H., Pacheco, B., Wang, L., Haight, J., Kassa, A., Danek, B., Pancera, M., Kwong, P. D., and Sodroski, J. (2010) Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol. Cell 37, 656-667
18. Jiang, S., Lin, K., Strick, N., and Neurath, A. R. (1993) HIV-1 inhibition by a peptide. Nature 365, 113
19. Furuta, R. A., Wild, C. T., Weng, Y., and Weiss, C. D. (1998) Capture of an early fusion-Active conformation of HIV-1 gp41. Nat. Struct. Biol. 5, 276-279
20. Chan, D. C., and Kim, P. S. (1998) HIV entry and its inhibition. Cell 93, 681-684
21. Melikyan, G. B., Egelhofer, M., and von Laer, D. (2006) Membrane-Anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J. Virol. 80, 3249-3258
22. Munoz-Barroso, I., Durell, S., Sakaguchi, K., Appella, E., and Blumenthal, R. (1998) Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J. Cell Biol. 140, 315-323
23. Colman, P. M., and Lawrence, M. C. (2003) The structural biology of type I viral membrane fusion. Nat. Rev. Mol. Cell Biol. 4, 309-319
24. Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273
25. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. C. (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430
26. Sollner, T. H. (2004) Intracellular and viral membrane fusion: a uniting mechanism. Curr. Opin. Cell Biol. 16, 429-435
27. Goni, F. M., and Alonso, A. (2006) Biophysics of sphingolipids I. Membrane properties of sphingosine, ceramides and other simple sphingolipids. Biochim. Biophys. Acta 1758, 1902-1921
28. Futerman, A. H., and Riezman, H. (2005) The ins and outs of sphingolipid synthesis. Trends Cell Biol. 15, 312-318
29. Merrifield, R. B., Vizioli, L. D., and Boman, H. G. (1982) Synthesis of the antibacterial peptide cecropin A (1-33). Biochemistry 21, 5020-5031
30. Wexler-Cohen, Y., Ashkenazi, A., Viard, M., Blumenthal, R., and Shai, Y. (2010) Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-Anchored peptides lacking the critical pocket domain. FASEB J. 24, 4196-4202
31. Garg, H., Joshi, A., Freed, E. O., and Blumenthal, R. (2007) Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. J. Biol. Chem. 282, 16899-16906
32. Lev, N., and Shai, Y. (2007) Fatty acids can substitute the HIV fusion peptide in lipid merging and fusion: an analogy between viral and palmitoylated eukaryotic fusion proteins. J. Mol. Biol. 374, 220-230
33. Hetru, C., Letellier, L., Oren, Z., Hoffmann, J. A., and Shai, Y. (2000) Androctonin, a hydrophilic disulphide-bridged nonhaemolytic anti-microbial peptide: a plausible mode of action. Biochem. J. 345(Pt. 3), 653-664
34. Ben-Efraim, I., Bach, D., and Shai, Y. (1993) Spectroscopic and functional characterization of the putative transmembrane segment of the minK potassium channel. Biochemistry 32, 2371-2377
35. Holguin, A., De Arellano, E. R., and Soriano, V. (2007) Amino acid conservation in the gp41 transmembrane protein and natural polymorphisms associated with enfuvirtide resistance across HIV-1 variants. AIDS Res. Hum. Retroviruses 23, 1067-1074
36. Chan, D. C., Chutkowski, C. T., and Kim, P. S. (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U. S. A. 95, 15613-15617
37. Wexler-Cohen, Y., and Shai, Y. (2009) Membrane-Anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action. PLoS Pathog. 5, e1000509
38. Eckert, D. M., and Kim, P. S. (2001) Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. U. S. A. 98, 11187-11192
39. Bewley, C. A., Louis, J. M., Ghirlando, R., and Clore, G. M. (2002) Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J. Biol. Chem. 277, 14238-14245
40. Baldwin, C. E., Sanders, R. W., Deng, Y., Jurriaans, S., Lange, J. M., Lu, M., and Berkhout, B. (2004) Emergence of a drugdependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J. Virol. 78, 12428-12437
41. Wexler-Cohen, Y., and Shai, Y. (2007) Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J. 21, 3677-3684
42. Liu, S., Lu, H., Niu, J., Xu, Y., Wu, S., and Jiang, S. (2005) Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem. 280, 11259-11273
43. Liao, Z., Cimakasky, L. M., Hampton, R., Nguyen, D. H., and Hildreth, J. E. (2001) Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res. Hum. Retroviruses 17, 1009-1019
44. Rawat, S. S., Johnson, B. T., and Puri, A. (2005) Sphingolipids: modulators of HIV-1 infection and pathogenesis. Biosci. Rep. 25, 329-343
45. Ablan, S., Rawat, S. S., Viard, M., Wang, J. M., Puri, A., and Blumenthal, R. (2006) The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion. Virol. J. 3, 104
46. Viard, M., Parolini, I., Rawat, S. S., Fecchi, K., Sargiacomo, M., Puri, A., and Blumenthal, R. (2004) The role of glycosphingolipids in HIV signaling, entry and pathogenesis. Glycoconj. J. 20, 213-222
47. Finnegan, C. M., Rawat, S. S., Puri, A., Wang, J. M., Ruscetti, F. W., and Blumenthal, R. (2004) Ceramide, a target for antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 101, 15452-15457
48. Vieira, C. R., Munoz-Olaya, J. M., Sot, J., Jimenez-Baranda, S., Izquierdo-Useros, N., Abad, J. L., Apellaniz, B., Delgado, R., Martinez-Picado, J., Alonso, A., Casas, J., Nieva, J. L., Fabrias, G., Manes, S., and Goni, F. M. (2010) Dihydrosphingomyelin impairs HIV-1 infection by rigidifying liquid-ordered membrane domains. Chem. Biol. 17, 766-775
49. Kuikka, M., Ramstedt, B., Ohvo-Rekila, H., Tuuf, J., and Slotte, J. P. (2001) Membrane properties of d-erythro-N-Acyl sphingomyelins and their corresponding dihydro species. Biophys. J. 80, 2327-2337
50. Epand, R. M. (2003) Cholesterol in bilayers of sphingomyelin or dihydrosphingomyelin at concentrations found in ocular lens membranes. Biophys. J. 84, 3102-3110
51. Hammache, D., Pieroni, G., Yahi, N., Delezay, O., Koch, N., Lafont, H., Tamalet, C., and Fantini, J. (1998) Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3. J. Biol. Chem. 273, 7967-7971
52. Finnegan, C. M., Rawat, S. S., Cho, E. H., Guiffre, D. L., Lockett, S., Merrill, A. H., Jr., and Blumenthal, R. (2007) Sphingomyelinase restricts the lateral diffusion of CD4 and inhibits human immunodeficiency virus fusion. J. Virol. 81, 5294-5304
53. Rawat, S. S., Viard, M., Gallo, S. A., Blumenthal, R., and Puri, A. (2006) Sphingolipids, cholesterol, and HIV-1: a paradigm in viral fusion. Glycoconj. J. 23, 189-197
54. Alfsen, A., Iniguez, P., Bouguyon, E., and Bomsel, M. (2001) Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol. 166, 6257-6265
55. Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., and Kappes, J. C. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896-1905
56. Buzon, V., Natrajan, G., Schibli, D., Campelo, F., Kozlov, M. M., and Weissenhorn, W. (2010) Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 6, e1000880